Mn Services Vermogensbeheer B.V. Acquires 1,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mn Services Vermogensbeheer B.V. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,500 shares of the biopharmaceutical company’s stock after buying an additional 1,200 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Regeneron Pharmaceuticals were worth $30,274,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in REGN. Mizuho Securities USA LLC raised its position in Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. grew its stake in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares in the last quarter. Golden State Equity Partners boosted its position in Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 1,272 shares in the last quarter. Finally, Fagan Associates Inc. boosted its position in Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $706.94 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business has a 50 day simple moving average of $698.68 and a 200-day simple moving average of $874.30. The firm has a market capitalization of $77.29 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.86 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on REGN shares. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Finally, BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.